Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02864992
Title	Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	EMD Serono Research & Development Institute, Inc.
Indications	lung adenocarcinoma
Therapies	Tepotinib
Age Groups:	senior \| adult
Covered Countries	USA \| POL \| NLD \| ITA \| ISR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUT